title: Preoperative preparation of high-risk, specifically hyperimmunized canine renal allograft recipients with total-lymphoid irradiation and cyclosporine.
abstract: Hyperimmunized subjects are a particularly high-risk and rapidly growing group in the patient population awaiting renal transplantation. In a search for methods designed to ameliorate the prognosis in such cases, dogs of defined DLA genotype were sensitized with DLA incompatible skin allografts and injections of buffy coat. Each recipient was challenged with a renal allograft bearing the same DLA incompatibilities. Five dogs received kidney transplants, without any other treatment, and rejected their transplants at 2.5, 4, 5, 6, and 6.5 days, respectively. Another four dogs were given a 9-11-week course (1760 +/- 35 cGy) of total-lymphoid irradiation (TLI), followed by rabbit antithymocyte globulin (ATG); these animals rejected their renal allografts at 7, 8, 14, and 17 days, respectively. Five other dogs were treated with TLI and received cyclosporine (CsA) and methylprednisolone (MPd) daily until graft rejection. Their renal allografts survived for 7.5, 8.5, 20, 62, and 227 days, respectively. Renal allografts placed in normal recipients under the same conditions of donor-recipient DLA incompatibility had a mean survival time of 12.4 days (range: 10-18 days). At the time of transplantation, the specific anti-DLA antibody titers in the recipients were 81 to 243 in the untreated dogs; 27 to 81 in the TLI-ATG-treated group, and 3 to 243 in the TLI-CsA/MPd-treated group. The titers fell within 24-48 hr after renal transplantation, to 3 to 81 in the untreated sensitized dogs; they were 3 to 9 in the TLI-ATG-treated group, and were 9 to 243 in the TLI-CsA/MPd treated group. The cytotoxic antibody titers reached postoperative peaks of 6500 to 200,000 in the untreated dogs; 729 to 6500 in the TLI-ATG-treated dogs, and 243 to 6500 in the TLI-CsA/MPd-treated recipients. The combined use of TLI and CsA/MPd can significantly inhibit the capacity of immunized recipients to muster a secondary humoral response to the DLA antigen(s) used in the sensitization process; such treatment also abrogates the ability of the recipients to reject renal allografts bearing the same DLA specificities in accelerated fashion. This effect of TLI and cyclosporine may be of relevance to current severe problems in high-risk hyperimmunized human renal transplant candidates.
authors.forename: F T
authors.initials: FT
authors.lastname: Rapaport
authors.forename: A G
authors.initials: AG
authors.lastname: Meek
authors.forename: A N
authors.initials: AN
authors.lastname: Arnold
authors.forename: S
authors.initials: S
authors.lastname: Miura
authors.forename: R
authors.initials: R
authors.lastname: Hayashi
authors.forename: S
authors.initials: S
authors.lastname: Strober
mesh_terms: D000818:Animals; D000920:Antibody-Dependent Cell Cytotoxicity; D003524:Cyclosporins / Q000627:therapeutic use*; D004285:Dogs; D005260:Female; D006649:Histocompatibility Antigens / Q000276:immunology*; D007114:Immunization; D007156:Immunologic Memory; D007165:Immunosuppression Therapy / Q000379:methods*; D007518:Isoantibodies / Q000276:immunology*; D016030:Kidney Transplantation; D008208:Lymphatic System / Q000528:radiation effects; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D016038:Skin Transplantation; D014916:Whole-Body Irradiation
chemical_list: D003524:Cyclosporins; D006649:Histocompatibility Antigens; D007518:Isoantibodies; D008775:Methylprednisolone